AIM-PATH: Antibody Intelligence for Modeling of Pharmacokinetics and Toxicity in Humans
University of North Carolina at Chapel Hill aims to build antibody drug-customized organ-on-chip models and three in-silico platforms focused on improving ADME-Tox predictions in humans including pregnant individuals, so developers of antibody-based medicines can better predict how these drugs work in the body and assess safety for populations often left out of trials, including during pregnancy.